Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

MAIA Biotechnology, Inc. (MAIA)

$1.15 +1.77% NYSE: MAIA · 15-min delayed
  • CHICAGO, Illinois
  • Public · NYSE: MAIA
  • 13 employees
$75.4MMarket cap
$0Revenue · FY2024
-$22.4MNet income
13Employees
MAIANYSE
2022IPO

About MAIA Biotechnology, Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Reported figures

Financial summary

Revenue FY2024
$0
Net income
-$22.4M
Total assets
$9.7M
Market cap
$75.4M

Source: SEC EDGAR · updated Jun 7, 2026

NYSE: MAIA
$1.15 +1.77%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$0.87 $2.95

52-week range

Market cap
$75.4M
Shares outstanding
65.6M
Open
—
Day range
–
Prev close
—
Volume
—
IPO date
Jul 28, 2022

MAIA Biotechnology, Inc. (MAIA) Stock Price

  • Reported a net loss of $22.4M in FY2024.
  • Trading 61% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review MAIA Biotechnology, Inc..

Write a review
Newsroom

News about MAIA Biotechnology, Inc.

News & sentiment via Polygon.io

FAQ

MAIA Biotechnology, Inc.: frequently asked questions

Is MAIA Biotechnology, Inc. an American company?

MAIA Biotechnology, Inc. is a US-based company headquartered in Chicago, Illinois, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is MAIA Biotechnology, Inc. headquartered?

MAIA Biotechnology, Inc. is headquartered in Chicago, Illinois, United States.

Is MAIA Biotechnology, Inc. publicly traded?

Yes — MAIA Biotechnology, Inc. is a publicly traded company. Its stock trades under the ticker symbol MAIA on the NYSE.

What does MAIA Biotechnology, Inc. do?

MAIA Biotechnology, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →